Magnetic Resonance Imaging Reveals Novel Insights into the Dual Mode of Action of Bisacodyl: A Randomized, Placebo‐controlled Trial in Constipation
Clinical Pharmacology & Therapeutics · 2025
DOI: 10.1002/cpt.3532 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Abdulsalam Aliyu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Nottingham NIHR Research Centre, University of Nottingham, Nottingham, UK. Hauptthemen laut MEDLINE: Constipation, Magnetic Resonance Imaging, Bisacodyl, Laxatives. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Bisacodyl is a widely used laxative that stimulates both motility and secretion. Our aim was to exploit the unique capabilities of MRI to define bisacodyl's mode of action. Two placebo‐controlled cross‐over trials were performed, one using a single dose of Bisacodyl 5 mg while the second dosed daily for 3 consecutive days. Serial MRI was performed every 75 minutes. Primary endpoint: ascending colon water content as assessed by T1AC AUC 300–450 minutes . Secondary endpoints included: small bowel water content, whole gut transit time (WGTT), colonic volumes, stool frequency, and consistency using Bristol Stool Form Score (BSFS). Exploratory endpoints: changes in the serial segmental volumes were quantified from the number of “mass movements” defined as episodes when segmental volume change from the previous scan was > 20% of baseline volume. We also measure the time to defecate after dosing. After 3 days of bisacodyl, ascending colon water content (T1) was 62% greater than after placebo, mean difference T1 AUC 300–450 minutes 50.2 (61.0) sec.min, 95% CI (9.2, 91.2), P = 0.02, while after a single dose difference was only 11% ( P = 0.58). Both single and repeated doses shortened WGTT ( P < 0.049) and time to defecate ( P 0.01). Only repeated doses significantly increased small bowel water content ( P < 0.03), the number of “mass movements” ( P = 0.048), bowel frequency ( P = 0.006), and BSFS ( P = 0.03). Repeated, compared to single dosing of Bisacodyl, additionally increases small bowel and colon water content and increases the number of “mass movements” thereby increasing its laxative effect. MRI is a non‐invasive, patient‐acceptable technique for evaluating drugs which alter secretion and/or motility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Nottingham NIHR Research Centre, University of Nottingham, Nottingham, UK.
- School of Medicine, University of Nottingham, Nottingham, UK.
- Sir Peter Mansfield Imaging Centre, University of Nottingham, Nottingham, UK.
- Sanofi, Barcelona, Spain.
- Sanofi, Frankfurt am Main, Germany.
- Sanofi, Neuilly-sur-Seine, France.
ORCID-Profile: Abdulsalam Aliyu, Neele Dellschaft, Caroline Hoad, Colin Crooks, Penny Gowland, Alexia Aran, Robert Lange, Maura Corsetti, Luca Marciani, Robin Spiller
Zitieren
APA
Aliyu, A., Dellschaft, N., Hoad, C., Williams, H., Gaudoin, E., Sulaiman, S., Crooks, C., Gowland, P., Aran, A., Lange, R., Bois De Fer, B., Corsetti, M., Marciani, L., & Spiller, R. (2025). Magnetic Resonance Imaging Reveals Novel Insights into the Dual Mode of Action of Bisacodyl: A Randomized, Placebo‐controlled Trial in Constipation. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3532
Vancouver
Aliyu A, Dellschaft N, Hoad C, Williams H, Gaudoin E, Sulaiman S, et al. Magnetic Resonance Imaging Reveals Novel Insights into the Dual Mode of Action of Bisacodyl: A Randomized, Placebo‐controlled Trial in Constipation. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3532
BibTeX
@article{Aliyu2025,
author = {Aliyu, Abdulsalam and Dellschaft, Neele and Hoad, Caroline and Williams, Hannah and Gaudoin, Emily and Sulaiman, Sarah and Crooks, Colin and Gowland, Penny and Aran, Alexia and Lange, Robert and Bois De Fer, Beatrice and Corsetti, Maura and Marciani, Luca and Spiller, Robin},
title = {Magnetic Resonance Imaging Reveals Novel Insights into the Dual Mode of Action of Bisacodyl: A Randomized, Placebo‐controlled Trial in Constipation},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
doi = {10.1002/cpt.3532}
}
EUVIMED